secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2026-05-26T20:55:02+00:00
Accession:  0001730430-26-000025
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa caps Baker Bros. voting power at 49.9% by waiving conversion rights
---------------------------------------------------------------------------

- Baker Bros. entities hold 12.78M A1 and 16.06M B1 shares; they waive conversion into A/B shares if ownership exceeds 49.9% voting rights.
- Waiver is irrevocable and unconditional; amendment requires at least 75% shareholder approval.
- Deed prohibits circumvention; any conversion attempt violating the cap is void ab initio.
- Other shareholder rights (voting, dividends, capital return) remain unaffected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000025/0001730430-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000173043026000025/knsa-20260521x8k.htm
  HTML page:      https://secwatch.observer/filing/0001730430-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer